

05.09.2017**RUSNANO's Portfolio Company "Nanolek" and South Korean SK Chemicals Are Launching a Joint Project for the Development and Production of Vaccines**

NANOLEK announces cooperation in joint developments, research and production of vaccines with SK Chemicals, one of the leading biopharmaceutical companies in South Korea. The agreement was signed within the framework of the Eastern Economic Forum

Within the framework of cooperation, the companies are planning to conduct joint research activities, as well as to transfer know-how and technology followed by the integrated production of several vaccines licensed by SK Chemicals at the NANOLEK's plant in the Kirov Region. The first products of this partnership are presented by vaccines for prevention of rotavirus infection and infection caused by human papilloma virus (HPV). Both vaccines are currently not included in the Russian National Calendar of Preventive Vaccinations for widespread immunization, but are recommended by doctors due to the high prevalence of these diseases, as well as the potential complications of these infections. Vaccines are widely used in Russia and worldwide.

According to the statement made by Minister of Health of the Russian Federation Veronika Skvortsova in autumn 2016, the National Calendar of Preventive Vaccinations can be expanded starting from 2019 with two new positions due to the production of local vaccines against rotavirus and chicken pox, thereby increasing the number of infectious diseases not affecting the Russian children up to the standards of the European calendars.

Preventive vaccination against human papilloma virus prevents infections caused by certain varieties of HPV, as well as cervical cancer, head and neck cancer, genital warts and some rarer tumors associated with this infection. The highest mortality is marked among women under 40.

SK Chemicals is specialized in the development and production of biotech drugs, including vaccines, in cooperation with leading international commercial and public organizations, such as Sanofi Pasteur, the Bill and Melinda Gates Foundation, etc. NANOLEK will become the first Russian partner of the company.

Vladimir Khristenko, President, NANOLEK: "In partnership with South Korean company "SK Chemicals," we are approaching a deeper level of cooperation covering not only the production of vaccines on a full cycle in our company, but also conducting joint research in the development and evaluation of the effectiveness and safety of drugs. Our joint goal is to make affordable the most modern vaccines for the Russian consumer in the most efficient and safe way. Our mission is to protect children and adults from serious infections and their consequences."

Jae Yong Ahn, Head of the Vaccine Business, SK Chemicals: "A Memorandum of Cooperation with NANOLEK is another important step that demonstrates the



capabilities and commitment of our company to the health care market through research, developments and further production of modern vaccines in Russia.”

About RUSNANO

RUSNANO was founded as a joint stock company in March 2011, through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO is instrumental in realizing government policies for nanoindustry growth, investing in financially effective high-technology projects that guarantee the development of new manufacturing within the Russian Federation. The company invests in nanotechnology companies directly and through investment funds. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. By the moment thanks to RUSNANO's investments 87 plants and R&D centers are launched in 32 regions of Russia.

Management of the investment assets of RUSNANO are carried out by a limited liability company established in December 2013, RUSNANO Asset Management. **Anatoly Chubais** is Chairman of its Executive Board.

Work to establish nanotechnology infrastructure and carry out educational programs is fulfilled by RUSNANO's **Fund for Infrastructure and Educational Programs**, which was also established during the reorganization of the Russian Corporation of Nanotechnologies.

Contact information:

10A Prospekt 60-letia Oktyabrya, Moscow, Russia 117036

Telephone: +7 (495) 988-5677, fax:+7 (495) 988-5399, e-mail:press@rusnano.com